Benitez Bruno A, Davis Albert A, Jin Sheng Chih, Ibanez Laura, Ortega-Cubero Sara, Pastor Pau, Choi Jiyoon, Cooper Breanna, Perlmutter Joel S, Cruchaga Carlos
Department of Internal Medicine, School of Medicine, Washington University, 8007, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Department of Neurology, School of Medicine, Washington University, St. Louis, MO, USA.
Mol Neurodegener. 2016 Apr 19;11:29. doi: 10.1186/s13024-016-0097-0.
Most sequencing studies in Parkinson's disease (PD) have focused on either a particular gene, primarily in familial and early onset PD samples, or on screening single variants in sporadic PD cases. To date, there is no systematic study that sequences the most common PD causing genes with Mendelian inheritance [α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), PARKIN, PTEN-induced putative kinase 1 (PINK1) and DJ-1 (Daisuke-Junko-1)] and susceptibility genes [glucocerebrosidase beta acid (GBA) and microtubule-associated protein tau (MAPT)] identified through genome-wide association studies (GWAS) in a European-American case-control sample (n=815).
Disease-causing variants in the SNCA, LRRK2 and PARK2 genes were found in 2% of PD patients. The LRRK2, p.G2019S mutation was found in 0.6 % of sporadic PD and 4.8 % of familial PD cases. Gene-based analysis suggests that additional variants in the LRRK2 gene also contribute to PD risk. The SNCA duplication was found in 0.8 % of familial PD patients. Novel variants were found in 0.8% of PD cases and 0.6 % of controls. Heterozygous Gaucher disease-causing mutations in the GBA gene were found in 7.1 % of PD patients. Here, we established that the GBA variant (p.T408M) is associated with PD risk and age at onset. Additionally, gene-based and single-variant analyses demostrated that GBA gene variants (p.L483P, p.R83C, p.N409S, p.H294Q and p.E365K) increase PD risk.
Our data suggest that the impact of additional untested coding variants in the GBA and LRRK2 genes is higher than previously estimated. Our data also provide compelling evidence of the existence of additional untested variants in the primary Mendelian and PD GWAS genes that contribute to the genetic etiology of sporadic PD.
大多数帕金森病(PD)的测序研究要么聚焦于特定基因,主要是在家族性和早发性PD样本中,要么是在散发性PD病例中筛查单个变异。迄今为止,尚无系统研究对欧美病例对照样本(n = 815)中具有孟德尔遗传的最常见PD致病基因[α-突触核蛋白(SNCA)、富亮氨酸重复激酶2(LRRK2)、帕金森病蛋白(PARKIN)、PTEN诱导的假定激酶1(PINK1)和DJ-1(大辅-顺子-1)]以及通过全基因组关联研究(GWAS)确定的易感基因[葡糖脑苷脂酶β酸(GBA)和微管相关蛋白tau(MAPT)]进行测序。
在2%的PD患者中发现了SNCA、LRRK2和PARK2基因中的致病变异。LRRK2基因的p.G2019S突变在0.6%的散发性PD和4.8%的家族性PD病例中被发现。基于基因的分析表明,LRRK2基因中的其他变异也会增加PD风险。SNCA重复在0.8%的家族性PD患者中被发现。在0.8%的PD病例和0.6%的对照中发现了新的变异。在7.1%的PD患者中发现了GBA基因的杂合型戈谢病致病突变。在此,我们确定GBA变异(p.T408M)与PD风险和发病年龄相关。此外,基于基因和单变异分析表明,GBA基因变异(p.L483P、p.R83C、p.N409S、p.H294Q和p.E365K)会增加PD风险。
我们的数据表明,GBA和LRRK2基因中其他未经检测的编码变异的影响高于先前的估计。我们的数据还提供了令人信服的证据,证明在主要的孟德尔和PD GWAS基因中存在其他未经检测的变异,这些变异促成了散发性PD的遗传病因。